CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia - Wikidata - wikimedia - TriplyDB

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

http://www.wikidata.org/entity/Q33239180

about

Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling γ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF Aβ Biomarkers for cognitive impairment and dementia in elderly people.Magnetic resonance spectroscopy in the diagnosis of dementia with Lewy bodies.Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review.Delirium and dementia with Lewy bodies: distinct diagnoses or part of the same spectrum?Cerebrospinal fluid biomarkers of Alzheimer's disease.Biomarkers for cognitive impairment in Parkinson disease.Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia The spectrum of cognitive impairment in Lewy body diseases Development of a novel cellular model of Alzheimer's disease utilizing neurosphere cultures derived from B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J embryonic mouse brain Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia.CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides.Cerebrospinal fluid biomarkers for dementia with lewy bodies.Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation Biomarkers in Alzheimer's disease.Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid.Magneto-immunocapture with on-bead fluorescent labeling of amyloid-β peptides: towards a microfluidized-bed-based operation.Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.Olfactory impairment predicts cognitive decline in early Parkinson's disease.Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.Neurochemical biomarkers in Alzheimer's disease and related disorders.Nanofluidic biosensing for beta-amyloid detection using surface enhanced Raman spectroscopy Current state and future directions of neurochemical biomarkers for Alzheimer's disease.Distinguishing Lewy body dementias from Alzheimer's disease.Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians.Problems associated with fluid biomarkers for Parkinson's disease.Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.Biomarkers in dementia with Lewy bodies: a review.CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.Interaction between pathogenic proteins in neurodegenerative disorders.

P2860

Q26850298-450DD2A4-A74D-4C3A-B561-5E72462DB386 Q28076999-42BAC2B0-D46B-4783-B792-C9D9226974BE Q28687678-2AF8E4DA-6EC2-4C54-90FA-AE2FACD44B50 Q30370745-D9987EE1-D8F4-49E8-B912-FC454F60112B Q30841801-E87768DF-23D0-4796-A6A4-0196A82ADD2F Q31146512-23307F04-2F48-4677-A628-0B22E63A3EAA Q33164331-D83976DC-6EAB-426C-AACB-77A4ED940EE9 Q33757828-59C11FF5-6391-4296-853D-1C22F1A5A7C0 Q33896664-58783260-A5AC-444E-8A47-967FC1D23C7B Q33936708-3EFC4F1B-124D-42D1-89F3-91E28BB73C0A Q34019751-50653800-54FD-4489-89C2-4760DBF7C68A Q34063838-C9395B8A-AF29-439C-AF59-31118676E3D8 Q34123736-FD1AC1B9-7163-4D1C-A65B-DC6DD36D49C8 Q34140382-A4D9474B-7C92-4337-858F-18B5DAEDEE54 Q34244772-E0287005-56E1-49DB-B718-F831B64F7DD3 Q34248241-1D97D712-428F-4AED-B7EC-A9F241EA7485 Q34315258-63AFB6F6-06C8-48B5-9500-697865D43ABF Q34394932-29AB939F-1F86-411D-A402-F317F1F42825 Q35113795-7EA185B4-8616-4365-B8F2-19324B4845DA Q35311113-92037A95-9E51-4C8D-A1BC-08EBA5A13CCA Q35709581-84425307-EF73-44DC-959D-A1E5AD203B35 Q35772659-B3178266-4B63-482F-8241-5A6C82F61979 Q35938758-3E59E40F-96E0-4867-8914-3CDD5664C6AC Q36351543-6D73A3BA-4506-457C-9AA4-7D7FFE0B1826 Q36366891-C26C559A-506F-4759-AB60-6732E0C4E344 Q36983997-6A7F5AF8-8370-4254-BD01-CB3F4450D3EE Q36985933-B84CCD30-C71D-459A-800E-F7D6104ADECB Q36998833-0DECE2C9-989E-4F5E-9A44-BF5B51C8413C Q37118083-810F7F17-222B-4350-91FB-E804AC37F163 Q37157835-BD1FB9F2-8F9D-4DEB-85F4-EE19AC79767E Q37215837-19B3F87E-96D2-43FD-A094-028EB6E1E9A7 Q37345484-CBD08857-BEA4-4144-8224-C16060807983 Q37418238-47B60C7C-702A-4230-A075-AF5ABDA5D776 Q37438267-0A6187AF-20F5-44A5-A2AF-739B5B485894 Q37693146-980C429F-5586-4105-87B2-E88C0CF01CD1 Q37800100-3E0B29CC-5DB6-4326-8216-595ED65B5F35 Q37800101-8AD51B9E-E01D-4507-99B1-DD8026F7108F Q37896548-AA961D92-2683-41AD-AEAE-8FAB150CDC37 Q37953330-52939F2B-5CC2-43C9-9490-D4F7B873F269 Q37969262-DF8D6F6D-3F60-4368-868A-FE2935835A92

P2860

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

http://www.wikidata.org/entity/Q33239180

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

CSF amyloid-beta-peptides in A ...... d Parkinson's disease dementia

@ast

CSF amyloid-beta-peptides in A ...... d Parkinson's disease dementia

@en

type

label

CSF amyloid-beta-peptides in A ...... d Parkinson's disease dementia

@ast

CSF amyloid-beta-peptides in A ...... d Parkinson's disease dementia

@en

prefLabel

CSF amyloid-beta-peptides in A ...... d Parkinson's disease dementia

@ast

CSF amyloid-beta-peptides in A ...... d Parkinson's disease dementia

@en

P1433

Q33239180-3CAB1F82-F54B-4B0C-84DF-396932EFF83F

P1476

Q33239180-9046F9B9-8C4C-4FD2-9C6D-E042873426F5

P2093

Q33239180-08F79062-C1A0-49E9-B03C-F647FD50AD94

Q33239180-2438DE67-0057-4F26-8980-C1694A3F91E4

Q33239180-52CCFC72-1923-476E-A94F-2B0E0EC31E16

Q33239180-54E276DC-39FE-42A9-90FC-C9D16D675115

Q33239180-5A958BD9-7C44-4F14-B81C-0AFA93B4C8DC

Q33239180-5B68BB4B-AA2C-403B-9518-5F135800A26A

Q33239180-A5D975C9-1237-47A9-A9A7-5B2B9BD0D0C8

Q33239180-B21F3C0D-2122-4B5B-883A-2F8F9E13B77A

Q33239180-DD7A1273-B932-4931-8025-2F9383B5B4B5

P2860

Q33239180-099953A2-7166-429D-890F-C90245C5D1D4

Q33239180-1688CFD0-4764-452C-9D3D-E6214607B4BD

Q33239180-19660116-B3B3-48DE-AB6B-8CB0DC7C384B

Q33239180-2110D142-E60A-44C0-BD64-CC71FB225EE9

Q33239180-211864CF-94F9-4708-A2BA-4BD1B1769AA8

Q33239180-2A32D7BB-6943-4814-A199-76E20EED189F

Q33239180-33608DD9-5896-44C1-B0B6-8E6F24F84F71

Q33239180-463F3CEF-78B6-4D1C-A1D6-25385C35E4E0

Q33239180-4657C263-8042-46A8-AAC3-968572C0C999

Q33239180-46F6EB0B-8509-4017-968B-CB175ED863C7

P304

Q33239180-D09A35E5-7879-4131-B3AA-0FEDF912C6F9

P31

Q33239180-5B6F6726-5DE2-4BDE-BB06-706D24D7C434

P356

Q33239180-6489FB89-1D48-4EAF-8855-D69AC965D3D6

P407

Q33239180-E67BAE77-57EC-46E9-84E5-D1E53D521095

P433

Q33239180-FE174A74-38FC-4E00-822F-D33CE24E392B

P478

Q33239180-0F697DAF-BB19-48B3-B756-1573E55BBE74

P50

Q33239180-1B3405EE-203E-4F59-AED9-8A49C8F22C6F

Q33239180-674E323C-8188-4D1D-A839-DF3788220B4D

Q33239180-AD50976B-0F14-45B0-9AC4-C1A2958A2CAF

Q33239180-CFCCDD27-1497-43EA-95FA-7728B6331B89

P577

Q33239180-3429BB98-4CAA-44AB-8BA8-2F0460346104

P5875

Q33239180-52630A70-F872-4139-A274-55E53E2DC3B2

P698

Q33239180-F0F1F273-694F-4BF2-A785-C67FFB7416C0

P921

Q33239180-86975E09-184B-4527-BE06-3422BA09BFD7

Q33239180-961CCE4C-84DB-4045-8DC9-C6EE7DD00802

Q33239180-C586D950-CD8D-4035-A9E9-23FA04D2E11E

P932

Q33239180-9FD8238C-F113-44BE-9815-2FA62069C8A9

P356

P1433

P1476

CSF amyloid-beta-peptides in A ...... d Parkinson's disease dementia

@en

P2093

Alexandr Smirnov

http://www.w3.org/2001/XMLSchema#string

Eckart Rüther

http://www.w3.org/2001/XMLSchema#string

Hans-Wolfgang Klafki

http://www.w3.org/2001/XMLSchema#string

Hermann Esselmann

http://www.w3.org/2001/XMLSchema#string

Katrin Sparbier

http://www.w3.org/2001/XMLSchema#string

Lukas Cepek

http://www.w3.org/2001/XMLSchema#string

Markus Otto

http://www.w3.org/2001/XMLSchema#string

Mirko Bibl

http://www.w3.org/2001/XMLSchema#string

Piotr Lewczuk

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is?

Solution structure of methionine-oxidized amyloid beta-peptide (1-40). Does oxidation affect conformational switching?

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein

Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation.

Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia.

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

P304

1177-1187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWL063

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 5

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P50

Johannes Kornhuber

Brit Mollenhauer

Claudia Trenkwalder

P577

2006-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7178798

http://www.w3.org/2001/XMLSchema#string

P698

16600985

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Parkinson's disease

P932

5403412

http://www.w3.org/2001/XMLSchema#string